A number of important human diseases are caused by the inherited or acquired deficiency of a single serum protein. These include diabetes mellitus, pituitary dwarfism, hemophilias A an B and the erythropoietin (Epo) responsive anemias. Many of these diseases are currently treated by repeated intravenous or subcutaneous injections of purified or recombinant proteins. Such therapies although often life-saving are inconvenient and expensive. Moreover in some cases there is insufficient recombinant protein available to treat all patients prophylactically while in others intermittent administration of recombinant protein fails to ameliorate all of the side effects of the disease. These problems have stimulated interest in the development of novel gene transfer approaches that could be used for the treatment of acquired and inherited serum protein deficiencies. The long term goal of the studies described in this continuing application is the development of a muscle based somatic gene transfer approach that can be used to stably program physiologically regulated therapeutic levels of Epo in the circulation of patients with Epo responsive anemias. The method to be used is based on findings from the first three years of this grant which have demonstrated that genetically modified skeletal myocytes can be used to stably deliver physiological levels of Epo to the systemic circulation of mice and monkeys. In the studies described below the investigators propose to 1) develop novel adenoviral, adeno-associated viral and plasmid vectors for in vivo gene transfer of the Epo cDNA into skeletal muscle; 2) test the ability of these vectors to stably deliver physiological levels of Epo to the circulation of mice and monkeys following IM injection; 3) develop tetracycline-regulatable and skeletal muscle specific Epo expression vectors and test them in vitro and in vivo; and 4) test the hypothesis that hypoxia-inducible transcriptional regulatory elements from the Epo, LDH-A, and PGK genes can be used to construct hypoxia inducible Epo expression vectors that can be used to deliver physiologically regulated Epo to the circulation following IM injection. Taken together these studies should lay the foundation for successful human gene therapy trials for patients with Epo responsive anemias. They should also be relevant to the treatment of a number of other acquired and inherited serum protein deficiencies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK048987-05
Application #
2706265
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Kitt, Cheryl A
Project Start
1994-09-30
Project End
1999-06-30
Budget Start
1998-09-25
Budget End
1999-06-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Kaji, E H; Leiden, J M (2001) Gene and stem cell therapies. JAMA 285:545-50
Marshall, D J; Palasis, M; Lepore, J J et al. (2000) Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer. Mol Ther 1:423-9
Leiden, J M (2000) Human gene therapy: the good, the bad, and the ugly. Circ Res 86:923-5
Svensson, E C; Marshall, D J; Woodard, K et al. (1999) Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 99:201-5
Marshall, D J; Leiden, J M (1998) Recent advances in skeletal-muscle-based gene therapy. Curr Opin Genet Dev 8:360-5
Ma, Y; Thornton, S; Duwel, L E et al. (1998) Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 161:1516-24
Svensson, E C; Black, H B; Dugger, D L et al. (1997) Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 8:1797-806
Tripathy, S K; Black, H B; Goldwasser, E et al. (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 2:545-50
Leiden, J M (1996) Adenovirus-mediated gene transfer as an in vivo probe of lipoprotein metabolism. Circulation 94:2046-51
Tripathy, S K; Svensson, E C; Black, H B et al. (1996) Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci U S A 93:10876-80

Showing the most recent 10 out of 11 publications